Finasteride effects on hypoxia and angiogenetic markers in benign prostatic hyperplasia

Urology

Volumn 68, Issue 2, 2006, Pages 436-441

  Lekas, Alexandros G ^a   Lazaris, Andreas C ^b   Chrisofos, Michael ^b,c   Papatsoris, Athanasios G ^b,c   Lappas, Dimitrios ^c   Patsouris, Efstratios ^b   Deliveliotis, Charalampos ^b,c  

^a GENERAL HOSPITAL OF NIKEA   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; FINASTERIDE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MONOCLONAL ANTIBODY; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TIME; TRANSURETHRAL RESECTION; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CELL HYPOXIA; ENZYME INHIBITORS; FINASTERIDE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC HYPERPLASIA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 33746814498     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2006.03.038     Document Type: Article

References (30)

1. Arrigh H.M., Guess H.A., Metter E., et al. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 16 (1990) 253-261
2. MacDonagh R., and Pearcy R. Quality of life aspects in urology-benign prostatic hyperplasia. World J Urol 17 (1999) 199-204
3. Puchner P.J., and Miller M.I. The effects of finasteride on hematuria associated with benign prostatic hyperplasia. a preliminary report. J Urol 154 (1995) 1779-1782
4. Sieber P.R., Rommmel F.M., Huffnagle H.W., et al. The treatment of gross hematuria secondary to prostatic bleeding with finasteride. J Urol 159 (1998) 1232-1233
5. Hochberg D.A., Basillote J.B., Armenakas N.A., et al. Decreased suburethral prostatic microvessel density in finasteride treated prostates. a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol 167 (2002) 1731-1733
6. Pareek G., Shevchuk M., Armenakas N.A., et al. The effect of finasteride on the expression of vascular endothelial growth factor and microvessel density. a possible mechanism for decreasing prostate bleeding in treated patients. J Urol 169 (2003) 20-23
7. Sandfeldt L., Bailey D., and Hahn R. Blood loss during transurethral resection of the prostate after 3 months of treatment with finasteride. Urology 58 (2001) 972-976
8. Theodoropoulos V., Lazaris A.C., Sofras F., et al. Hypoxia-inducible factor 1α expression correlates with angiogenesis and unfavourable prognosis in bladder cancer. Eur Urol 46 (2004) 200-208
9. Haggstrom S., Torring N., Moller K., et al. Effect of finasteride on vascular endothelial growth factor. Scand J Urol 36 (2002) 182-187
10. Foley S.J., Soloman L.Z., Wedderburn A.W., et al. A prospective study of the natural history of hematuria associated with benign prostatic hyperplasia and the effect of finasteride. J Urol 163 (2000) 496-498
11. Kearney M., Bingham J., Bergland R., et al. Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia. J Urol 167 (2002) 2489-2491
12. Mebust W.K., Holtgrewe H.L., Cockett A.T.K., et al. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients. J Urol 141 (1989) 243-247
13. Burchardt M., Burchardt T., Chen M.W., et al. Vascular endothelial growth factor-a expression in the rat ventral prostate gland and the early effect of castration. Prostate 43 (2000) 184-194
14. Lekas E., Bergh A., and Damber J.-E. Effects of finasteride and bicalutamide on prostate blood flow in the rat. BJU Int 85 (2000) 962-965
15. Franck-Lissbrant I., Haggestrom S., Damber J.E., et al. Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139 (1998) 451-454
16. Miller M.I., and Puchner P.J. Effects of finasteride on hematuria associated with benign prostatic hyperplasia. long-term follow-up. Urology 51 (1998) 237-240
17. Bigler S.A., Deering R.E., and Brawer M.K. Comparison of microscopic vascularity in benign and malignant prostate tissue. Hum Pathol 24 (1993) 220-226
18. Stefanou D., Batistatou A., Kamina S., et al. Expression of vascular endothelial growth factor (VEGF) and association with microvessel density in benign prostatic hyperplasia and prostate cancer. In vivo 18 (2004) 155-160
19. Bailey D.M., and Foley S.J. Microvascular anatomy in patients with recurrent hematuria related to prostatic hypertrophy. BJU Int 85 (2000) 70-73
20. Donohue J., Hayne D., Karnik U., et al. Randomized, placebo-controlled trial showing that finasteride reduces prostatic vascularity rapidly within 2 weeks. BJU Int 96 (2005) 1319-1322
21. Donohue J., Sharma H., Abraham R., et al. Transurethral prostate resection and bleeding. a randomized, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol 168 (2002) 2024-2026
22. Andriole G., Bostwick D., Civantos F., et al. The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer. current state of knowledge. J Urol 174 (2005) 2098-2104
23. Mellon J.K. The finasteride prostate cancer prevention trial (PCPT)-what have we learned?. Eur J Cancer 41 (2005) 2016-2022
24. Talks K.L., Turley H., Gatter K.C., et al. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumour-associated macrophages. Am J Pathol 157 (2000) 411-421
25. Coffey R.N., Morrissey C., Taylor C.T., et al. Resistance to caspase-dependent, hypoxia-induced apoptosis is not hypoxia-inducible factor-1 alpha mediated in prostate carcinoma cells. Cancer 103 (2005) 1363-1374
26. 2 homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12 (1998) 149-162
27. Carmeliet P., Dor Y., Herbert J.M., et al. Role of HIF-1 alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394 (1998) 485-490
28. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia inducible factor 1. Mol Cell Biol 16 (1996) 4604-4613
29. Du Z., Fujiyama C., Chen Y., et al. Expression of hypoxia-inducible factor 1alpha in human normal, benign, and malignant prostate tissue. Chin Med J (Engl) 116 (2003) 1936-1939
30. Gormley G.J., Stoner E., Bruskewitz R.C., et al. the Finasteride Study Group. The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327 (1992) 1185-1191